Curious to see your top suppliers emissions?
Book a demo for a pilot project
Book a demo for a pilot project
Labcorp Drug Development Inc., a prominent player in the global life sciences industry, is headquartered in the United States. Founded in 1971, the company has established itself as a leader in drug development and laboratory services, providing comprehensive solutions to pharmaceutical and biotechnology clients. With a strong presence across North America, Europe, and Asia, Labcorp offers a wide range of services, including clinical trial management, laboratory testing, and biomarker development.
Renowned for its innovative approach, Labcorp's core offerings are distinguished by advanced technology and a commitment to improving patient outcomes. The company has achieved significant milestones, including the successful management of thousands of clinical trials and the integration of cutting-edge diagnostics. As a trusted partner in the drug development process, Labcorp continues to enhance its market position through strategic collaborations and a focus on scientific excellence.
+49 vs industry average
Labcorp Drug Development Inc.’s score of 79 is higher than 85% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Research Services has below-average carbon intensity
The Research Services industry has reduced its overall emissions by 19% since 2018
No reported emissions data is available for Labcorp Drug Development Inc. yet.
Labcorp Drug Development Inc., headquartered in the US, currently does not report specific carbon emissions data for the most recent year, as indicated by the absence of emissions figures. The company is a current subsidiary of Labcorp Holdings Inc., which may influence its climate commitments and reporting practices.
Labcorp Drug Development Inc. inherits its climate initiatives and targets from Labcorp Holdings Inc. at a cascade level of 1. However, there are no documented reduction targets or significant climate pledges available for Labcorp Drug Development Inc. at this time. This lack of specific data suggests that the company may still be in the process of establishing or formalising its climate strategy.
In the broader context, companies in the pharmaceutical and drug development sector are increasingly focusing on sustainability and carbon reduction, often aligning with industry standards such as the Science Based Targets initiative (SBTi) and the Carbon Disclosure Project (CDP). As Labcorp Drug Development Inc. continues to develop its climate commitments, it may adopt similar frameworks to enhance its environmental performance and transparency.
Access structured emission data, company specific factors and auditable source documents
No climate goals have been disclosed for Labcorp Drug Development Inc. yet.
No scope 3 category breakdown has been disclosed yet.


No peer comparison is available for Labcorp Drug Development Inc. yet.
You’re welcome to quote or reference data from this page, but please include a visible link back to this URL. Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.
Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers
Learn more